Author provides a bullish thesis on Sellas Life Sciences based on trial catalysts and potential buyout valuation.
SLS — LONG The author argues Sellas Life Sciences is significantly undervalued, with a possible buyout valuation of $10-30 billion translating to $45-125 per share. The company's Phase 3 GPS trial has had slower-than-expected event accumulation, but the author expects catalysts to emerge within the next three months.
10bil buy out floor, 20 mid, 30 high. That's 45-125$ a share, expect the catalysts to start popping in the next 3 months.
This Reddit post, published January 02, 2026, features u/Crew4815162342 discussing SLS. 1 trade idea extracted by AI with direction and confidence scoring.
Speakers: u/Crew4815162342 · Tickers: SLS